4-氨基丁酸叔丁酯盐酸盐 | 58640-01-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-氨基丁酸叔丁酯盐酸盐
• 中文别名: H-Y-ABU-OTBU盐酸盐；4-氨基丁酸叔丁基酯盐酸盐
• 英文名称: tert-butyl 4-aminobutanoate hydrochloride
• 英文别名: tert-butyl 4-aminobutyrate hydrochloride；tert-butyl γ-aminobutyrate hydrochloride；tert-butyl 4-aminobutanoate;hydrochloride
• CAS: 58640-01-0
• 化学式: C₈H₁₇NO₂*ClH
• 分子量: 195.689
• InChiKey: CZVNLCOJFFYZPG-UHFFFAOYSA-N

物化性质

• 熔点：
  85-87oC
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.49
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境中保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Gamma-Abu-Otbu HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Gamma-Abu-Otbu HCl
CAS number: 58640-01-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H17NO2.ClH
Molecular weight: 195.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基丁酸叔丁酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 生成 三氟乙酸
  参考文献：
  名称：

  ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS

  摘要：

  这项发明涉及新型结合物-前药偶联物（APDCs），其中结合物与动力蛋白纺锤体抑制剂的非活性前体化合物偶联，以及抗体药物偶联物ADCs以及制备这些APDCs和ADCs的方法。

  公开号：

  US20180169256A1
• 作为产物：
  描述：

  tert-butyl 4-(((benzyloxy)carbonyl)amino)butanoate 在 palladium 10% on activated carbon 、 氢气 、 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 6.5h， 以51%的产率得到4-氨基丁酸叔丁酯盐酸盐
  参考文献：
  名称：

  [EN] LIPOPEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN DISORDERS
  [FR] COMPOSÉS LIPOPEPTIDES DESTINÉS AU TRAITEMENT DE TROUBLES DE LA DOULEUR

  摘要：

  这项发明基于发现一种具有镇痛特性的新细菌化合物，可用作治疗内脏疼痛等疼痛疾病的新工具。研究参与益生菌大肠杆菌菌株Nissle 1917（EcN）镇痛特性的机制，发明者表征了EcN产生的氨基脂肪酸，这些氨基脂肪酸显示出EcN的镇痛特性。其中一种化合物抑制了辣椒素诱导的结肠膨胀过敏，辣椒素是一种非常强力的伤害性化合物，通过GABA B受体发挥作用。此外，发明者证明了这种化合物能够穿过细胞上皮屏障（如肠上皮）。因此，该发明涉及一种源自γ-氨基丁酸的脂肽化合物。该发明还涉及根据该发明用于治疗疼痛障碍，如体表疼痛和内脏疼痛的脂肽化合物。

  公开号：

  WO2018197666A1

文献信息

• [EN] BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES D’ARYLSPHINGOSINE-1-PHOSPHATE BICYCLIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2011017561A1

  公开（公告）日：2011-02-10

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

  提供具有在一个或多个SlP受体上拮抗活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后可以在SlP受体上表现为拮抗剂。
• Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20170291911A1

  公开（公告）日：2017-10-12

  The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

  该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶（ATR）的化合物和组合物，以及它们的使用方法。
• Halo sulfonyl aryl boronates
  申请人：——

  公开号：US20040116701A1

  公开（公告）日：2004-06-17

  The present invention relates to halo sulfonyl aryl boronates of the general formula (I): 1 wherein Arylene designates a carbocyclic or heterocyclic, aromatic ring system comprising 1-3 rings; R 1 , R 2 and R 3 are, independently, hydrogen, C 1-6 alkyl, C 1-6 alkoxy, halogen, nitro, cyano or phenyl; X is fluoro, chloro or bromo; and Y is a boroxine moiety attached via a bond from Arylene to one of the boron atoms of a boroxine ring which ring has a group of the formula—Arylene(R 1 )(R 2 )(R 3 )SO 2 X, wherein Arylene, R 1 , R 2 , R 3 and X are as defined above, at each of the other two boron atoms of the boroxine ring, or Y is a boronic acid group or a boronic ester group. The invention also relates to the preparation of the compounds of formula (I) and to their use in organic synthesis.

  本发明涉及一般式（I）的卤磺酰基芳基硼酸酯： 其中Arylene表示一个含有1-3个环的碳环或杂环芳香环系统； R1、R2和R3分别为氢、C1-6烷基、C1-6烷氧基、卤素、硝基、氰基或苯基； X为氟、氯或溴；以及 Y是通过一条键连接到Arylene上的硼氧杂环基，该环具有一个式为Arylene(R1)(R2)(R3)SO2X的基团，在硼氧杂环的另外两个硼原子上，或Y是硼酸基团或硼酯基团。 该发明还涉及一般式（I）化合物的制备以及它们在有机合成中的应用。
• [EN] DIRECTED CONJUGATION TECHNOLOGIES<br/>[FR] TECHNOLOGIES DE CONJUGAISON DIRIGÉE
  申请人：KLEO PHARMACEUTICALS INC

  公开号：WO2021102052A1

  公开（公告）日：2021-05-27

  Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

  本公开提供了用于将各种感兴趣的分子与目标剂进行定点偶联的技术。在某些实施方式中，本公开利用目标结合分子以提供高偶联效率和选择性。在某些实施方式中，所提供的技术可用于制备抗体偶联物。
• [EN] AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE CYANURE D'AZOLE METHYLIDENE ET LEUR UTILISATION COMME MODULATEURS DE PROTEINE KINASE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003106455A1

  公开（公告）日：2003-12-24

  The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

  本发明涉及唑衍生物，尤其是用作药物活性化合物的唑衍生物，以及包含这种唑衍生物的药物制剂。所述唑衍生物是蛋白激酶信号通路的调节剂，尤其是涉及c-Jun N端激酶和/或糖原合酶3的那一种。本发明还涉及新颖的唑衍生物以及它们的制备方法。X是O、S或NR0，其中R0是H或未取代或取代的C1-C6烷基；A是2-吡啶基，3-吡啶基，4-吡啶基，吡啶唑基，吡唑啉基，吡嗪基或三嗪基团。